PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...
The study was funded by Janssen Oncology. Access disclosures for Dr. Yu. Only patients with persistent EGFR in circulating tumor DNA (ctDNA) after initiating therapy with osimertinib are randomized to ...
together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback